Rilvegostomig Biosimilar - Research Grade

Human

PD-1xTIGIT

>1mg/ml

Human IgG1(K214R/L234F/L235E/P331S/Y349C/T366S/L368A/Y407V)(F126C/K214R/C220V/L234F/L235E/P331S/S354C/T366W)-Kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue Ice

PD-1 and TIGIT are inhibitory checkpoints whose combined blockade is a prominent strategy for restoring T-cell function in cancer immunotherapy research. This research-grade, non-therapeutic biosimilar analog of rilvegostomig is a bispecific recombinant human IgG1 antibody engineered to engage both PD-1 and TIGIT, supplied for research use only (RUO). It is purified to a low-endotoxin standard suitable for in vivo studies and manufactured in scalable milligram to gram quantities for high-throughput and bulk laboratories. The reagent supports dual-checkpoint binding and blocking assays, in vitro T-cell function screening, control applications, and preclinical tumor immunology models.

AZD 2936

Ion Exchange Chromatography

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.